Internal Medicine, Endocrinology, Diabetes, & Metabolism · Zanesville, OH
NPI
1124189592
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2315 Maple Ave
Zanesville, OH, 43701
Phone (740) 586-6690
Groups this clinician bills Medicare through
Medicare paid, 2024
$54K
1,325 services
Medicare patients, 2024
462
Average age 70
Drug cost, 2024
$8.5M
11,499 prescriptions
Company payments, 2025
$1,984
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammad T Ijaz was code 99214 (office e&m - established), 578 times for 370 patients. In total Mohammad T Ijaz billed 1,325 services in 9 codes, and Medicare paid $54K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 578 | 370 | $61.58 | $36K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 407 | 319 | $11.76 | $4,786 |
| 95251 Test - Miscellaneous | Facility | 201 | 112 | $23.88 | $4,801 |
| 99204 Office E&M - New | Facility | 85 | 85 | $86.19 | $7,326 |
| 99213 Office E&M - Established | Facility | 40 | 39 | $34.43 | $1,377 |
By year: 2022 $51K for 886 services; 2023 $51K for 903 services; 2024 $54K for 1,325 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammad T Ijaz prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 1,363 prescriptions and refills. In total Mohammad T Ijaz wrote 11,499 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 1,363 | 1,467 | 222 | $1.5M |
| Jardiance Empagliflozin | 1,182 | 1,928 | 249 | $1.1M |
| Ozempic Semaglutide | 973 | 1,218 | 170 | $1.2M |
| Levothyroxine Sodium Generic | 727 | 1,313 | 176 | $4,570 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 495 | 963 | 146 | $84K |
| Metformin Hcl Er Metformin Hcl | 483 | 992 | 139 | $6,544 |
| Trulicity Dulaglutide | 428 | 460 | 95 | $435K |
| Tresiba Flextouch U-100 Insulin Degludec | 381 | 802 | 103 | $269K |
| Novolog Flexpen Insulin Aspart | 342 | 557 | 122 | $108K |
| Synthroid Levothyroxine Sodium | 275 | 520 | 65 | $20K |
| Humalog Kwikpen U-100 Insulin Lispro | 252 | 473 | 97 | $88K |
| Methimazole Generic | 208 | 342 | 45 | $1,207 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 201 | 376 | 72 | $17K |
| Metformin Hcl Generic | 187 | 424 | 66 | $1,451 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 171 | 344 | 60 | $94K |
Brand drugs: 7,918 claims; generic drugs: 2,702 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammad T Ijaz $1,984 ($1,984 in general payments such as food, travel and fees) from 15 companies. The largest payer was Medtronic, Inc. with $1,140.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 9 | $1,140 |
| Insulet Corporation PODD | 5 | $217 |
| Novo Nordisk Inc NVO | 7 | $208 |
| Sequel Med Tech, LLC | 1 | $139 |
| Corcept Therapeutics CORT | 3 | $98.32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31.14 |
| Amgen Inc. AMGN | 1 | $18.69 |
| Lilly USA, LLC LLY | 1 | $18.34 |
| Acella Pharmaceuticals, LLC | 1 | $18.18 |
| Dexcom, Inc. DXCM | 1 | $18.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.